MIRM

Mirum Pharmaceuticals Inc

Pictet Asset Management Holding SA boosted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 6.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 577,274 shares of the company's stock after purcha...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference...

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stifel Nicolaus boosted their target price on shares of Mirum Pharmaceuticals from $125.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday...

Biogen (BIIB) delivered earnings and revenue surprises of +20.87% and +10.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals (NASDAQ:MIRM) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and one ha...

Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $95.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an...